Skip to content

Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective.

Álvaro López-díaz, Manuel Murillo-Izquierdo, Elisa Moreno-Mellado

The British journal of psychiatry : the journal of mental science August 1, 2019 DOI: 10.1192/bjp.2019.102 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Theoretical or philosophical paper Peer reviewed
Topics Depression Ketamine Esketamine
Keywords Antidepressants
Citations 21
Key points Argues that ketamine therapy for treatment-resistant depression in European national health systems may only be considered after all evidence-based antidepressant strategies have been attempted, and explains the ethical, regulatory, and procedural framework for its off-label use.

Abstract

Ketamine therapy for treatment-resistant depression in European national health systems may only be considered after attempting all evidence-based antidepressant strategies outlined in clinical guidelines. This paper seeks to explain the ethical, regulatory and procedural framework for the off-label use of ketamine for treatment-resistant depression within a public healthcare system.Declaration of interestNone.

Comparable studies

Other theoretical and historical papers on ketamine for depression, most cited first.

Explore topics

By condition and practice